$1,001.74 general Payment -- Takeda Pharmaceuticals to Dr. Gregory Evans
Takeda Pharmaceuticals pays Hematologist $1001.74 for Entresto Education in NC
This page provides a detailed analysis of a $1,001.74 general payment from Takeda Pharmaceuticals to Dr. Gregory Evans. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $1,001.74 |
| Payment Type | general |
| Payment Nature | Education |
| Pharmaceutical Company | Takeda Pharmaceuticals |
| Physician | Dr. Gregory Evans |
| NPI Number | 1841967809 |
| Physician Specialty | Hematology |
| Location | Durham, NC |
| Date of Payment | 2024-12-07 |
| Related Drug/Device | Entresto |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Takeda Pharmaceuticals made a $1.0K general payment to Gregory Evans, a Hematology specialist in Durham, NC. The payment was associated with Entresto. The payment of $1001.74 to Dr. Gregory Evans by Takeda Pharmaceuticals for "Entresto" education is a moderate amount for this specialty. This payment falls under 'general' payment type and 'Education' nature, suggesting a focus on product knowledge. The payment was made on December 7, 2024, to a Hematology specialist in Durham, NC.
Patient Guidance: What This Payment Means for You
This payment was for educational purposes related to a medication. Discuss with your doctor if you have questions about their professional development or the medications they prescribe. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
While educational payments are common in Hematology, the specific drug 'Entresto' is more commonly associated with cardiology, making this payment's relevance to the specialty worth noting.
Regulatory Context: Sunshine Act Requirements
Payments to physicians by manufacturers are subject to disclosure under the Sunshine Act, requiring transparency in these financial relationships.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- drug-education
- takeda-pharmaceuticals
- entresto
- hematology
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $1.0K payment for?
This was a general payment of $1.0K from Takeda Pharmaceuticals to Gregory Evans, categorized as "Education". It was associated with Entresto. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Gregory Evans accept pharmaceutical money?
Yes, Gregory Evans received this $1.0K payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Gregory Evans's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $1.0K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Hematology?
To compare this payment against Hematology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hematology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Gregory Evans's relationship with Takeda Pharmaceuticals?
The payment amount is specific, indicating a defined educational activity. This $1.0K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Hematology?
The drug mentioned, Entresto, is typically used for cardiovascular conditions, which may be outside the primary scope of Hematology.
What should patients do after learning about this payment?
This payment was for educational purposes related to a medication. Discuss with your doctor if you have questions about their professional development or the medications they prescribe.
What else should I know about this general payment?
The payment ID 'OP-MNIOITEB-22N9UV' allows for direct lookup of this transaction.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.